<DOC>
	<DOCNO>NCT00036634</DOCNO>
	<brief_summary>This study evaluate two dos tenofovir alafenamide versus tenofovir disoproxil fumarate ( tenofovir DF ) .</brief_summary>
	<brief_title>A Dose Escalation Study Tenofovir Alafenamide Treatment-Naive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion Criteria HIV1 RNA level great equal 30,000 copies/mL CD4 count great equal 200 cells/mm3 Serum creatinine &lt; 1.5 mg/dl Hepatic transaminases less equal 2.5 time upper limit normal Total bilirubin less equal 1.5 mg/dL Adequate hematologic function Serum amylase less equal 1.5 time upper limit normal Serum phosphate great equal 2.2 mg/dL Not pregnant Exclusion Criteria Prior treatment antiretroviral therapy Immunization within 30 day study entry A new AIDS defining condition within 30 day study entry Receiving nephrotoxic agent , probenecid , chemotherapeutic agent , corticosteroid , interleukin2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>treatment naive</keyword>
</DOC>